These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 21649727

  • 21. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N, Habibi MS, Brown A.
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM, Ahmed A, Mahmoud S, Nabegh L, El Gohary I, Obadan I, Hafez T, Ghoraba D, Aziz AA, Metaoei M.
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
    Perrella A, Sbreglia C, Atripaldi L, Esposito C, D'Antonio A, Perrella O.
    Scand J Gastroenterol; 2010 Mar; 45(2):250-5. PubMed ID: 19968615
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
    El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM.
    World J Gastroenterol; 2014 Apr 28; 20(16):4681-91. PubMed ID: 24782620
    [Abstract] [Full Text] [Related]

  • 32. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
    Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.
    Hepatology; 2008 Jun 28; 47(6):1884-93. PubMed ID: 18508296
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA.
    J Viral Hepat; 2008 Aug 28; 15(8):591-9. PubMed ID: 18482284
    [Abstract] [Full Text] [Related]

  • 36. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR, Imoto S, Mita K, Taniguchi M, Sasase N, Muramatsu A, Kudo M, Kitai S, El-Shamy A, Hotta H, Hayashi Y.
    Digestion; 2009 Aug 28; 79(1):36-9. PubMed ID: 19246919
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.